Progress in the management of T3-4 adenocarcinoma of the prostate

European Journal of Cancer Part A

Volumn 33, Issue 4, 1997, Pages 555-559

  Zietman, A L ^a   Shipley, W U ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DIETHYLSTILBESTROL; FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BEAM THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RAT; RECTUM HEMORRHAGE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031009282     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00442-X     Document Type: Article

References (33)

1. Hanks GE, Leibel SA, Krall JM, Kramer S. Patterns of care studies: dose-response observations for local control of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1985, 11, 153-157.
2. Morton RA, Steiner MS, Walsh PC. Cancer control following anatomical radical prostatectomy: an interim report. J Urol 1991, 145, 1197-1200.
3. Zincke H, Utz DC, Taylor WF. Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol 1986, 135, 1199-1205.
4. Suit HD, Shalek RJ, Wette R. Radiation response of CÈH mouse mammary carcinoma evaluated in terms of cellular radiosensitivity. In Shalek RJ, et al., eds. Cellular Radiation Biology. Baltimore, Williams and Wilkins Co., 1965, 5114-5130.
5. Partin AW, Yoo J, Carter HB, et al. Use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150, 110-114.
6. Hanks GE, Diamond JJ, Krall JM, et al. A ten year follow up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys 1987, 13, 499-505.
7. Perez CA, Pilepich MV, Garcia D, et al. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: experience at the Mallinckrodt Institute of Radiology. Natl Cancer Inst Monog 1988, 7, 85-94.
8. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. Natl Cancer Inst Monogr 1988, 7, 47-60.
9. Fuks Z, Leibel S, Wallner K, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125-I implantation. Int J Radiat Oncol Biol Phys 1992, 21, 537-547.
10. Griffin T, Krall J, Russell K, et al. Fast neutron irradiation of locally advanced prostate cancer. Semin Oncol 1988, 15, 359-367.
11. Holtzman M, Carlton CE, Scardino PT. The frequency and morbidity of local recurrence after definitive radiotherapy for stage 3 prostate cancer. J Urol 1991, 146, 1578-1582.
12. Scardino P, Frankel J, Wheeler T, et al. The prognostic significance of post-irradiation biopsy results in patients with prostatic carcinoma. J Urol 1986, 135, 510-513.
13. Kabalin J, Hodge K, McNeal J, et al. Identification of residual cancer in the prostate following radiation therapy: the role of trans-rectal ultrasound guided biopsy and PSA. J Urol 1979, 142, 326-331.
14. Dugan T, Shipley W, Young R, et al. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histologic grade and current PSA levels. J Urol 1991, 146, 1313-1316.
15. Kuban D, El-Mahdi A, Schellhammer P. The significance of post-irradiation prostate biopsy with long-term follow up. Int J Radial Oncol Biol Phys 1992, 24, 409-414.
16. Andriole G. Serum prostate-specific antigen: the most useful tumor marker. J Clin Oncol 1992, 10, 1205-1206.
17. Stamey T, Yang N, Hay A, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317, 909-912.
18. Schellhammer PF, El-Mahdi AM, Wright GL, Kolm P, Ragle R. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of the prostate. Urology 1993, 42, 13-20.
19. Pisansky TM, Cha SS, Earle JD, et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993, 11, 2158-2165.
20. Zietman AL, Coen JJ, Shipley WU, et al. Radical radiation therapy in the management of prognostic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994, 151, 640-645.
21. Zietman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys 1995, 32, 287-292.
22. Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Kelson S, Fuks Z. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase I dose-escalation study. J Urol 1994, 152, 1792-1798.
23. Shipley WU, Verhey LJ, Munzenrider JE, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995, 32, 3-12.
24. Soffen EM, Hanks GE, Hunt MA, Epstein BE. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. Int J Radiat Oncol Biol Phys 1992, 24, 485-491.
25. Lichter AS, Sandler HM, Robertson JM, et al. Clinical experience with three-dimensional planning. Semin Rad Oncol 1992, 2, 257-263.
26. Benk VA, Adams JA, Shipley WU, et al. Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-4 prostatic carcinoma. Int J Radiat Oncol Biol Phys 1993, 26, 551-557.
27. Corn BW, Hanks GE, Schultheiss TE, Hunt MA, Lee TR, Coia LR. Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys 1995, 32, 325-330.
28. Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am, in press
29. Thompson I, Lowe B, Carrol P, et al. A multicenter study of hormonal 'down-staging' of clinical stage C carcinoma of the prostate followed by radical prostatectomy. J Urol 1991, 145, 316A.
30. Snellr Z, Hop W, Carpentier P, et al. Prognosis and prostate volume changes during endocrine management of prostate carcinoma: a longitudinal study. J Urol 1992, 147, 962.
31. Green N, Bodner H. Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Oncol Biol Phys 1974, 10, 971.
32. Pilepich MV, Krall JM, Al-Sarraf M, et al Androgen deprivation with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995, 45, 616-623.
33. Shipley WU, Prout GR Jr, Coachman NM, et al. Radiation therapy for localized prostatic carcinoma: the experience at the Massachusetts General Hospital (1973-1981). Natl Cancer Int 1988, 7, 67-74.